profit from every $100 of sales.
$0$100
enVVeno Medical
$6.52+1.09% today
-73.5% in 1 year
1-year low $6.451-year high $24.64
Trading close to its lowest price of the past year.
The essentials
Four questions every investor asks, answered in one line each.
more sales each year, on average.
0%20% a year
It has no yearly profit to compare the price with.
CheapExpensive
of earnings would pay off all its debt.
No debt5 years
Money in, money out
What enVVeno Medical sold, what it kept, and what it did with the cash.
Sales went from $0 in 2022 to $0 in 2025, with -$19.5 million of profit last year.
SalesProfit
enVVeno Medical vs. similar companies
How it compares with the largest companies in its industry.
| Company | Profit from $100 of sales | Sales growth a year | Price per $1 of profit |
|---|---|---|---|
| enVVeno Medical | No profit yet | ||
 Boston Scientific | 22.6× · Fair price | ||
 Koninklijke Philips | 29.7× · Fair price | ||
 Steris | 31.8× · Expensive | ||
 Zimmer Biomet Holdings | 28.8× · Fair price |
AI analysis
An AI analyst reads enVVeno Medical's last five years, its segments, earnings, insiders and peers, and writes the bull case, the bear case and what the price expects.
Run the AI analysisFull statementsIncome, balance sheet and cash flow, year by year
Income statement
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| 0 | 0 | 0 | 0 | |
| – | – | – | – | |
| -25 | -25 | -24 | -21 | |
| -24 | -25 | -23 | -20 | |
| -25 | -24 | -22 | -19 | |
| -77.00 | -66.85 | -44.53 | -33.06 | |
| – | – | – | – | |
| – | – | – | – | |
| – | – | – | – |
Balance sheet
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total assets | 42 | 49 | 45 | 30 |
| Cash | 5 | 4 | 2 | 3 |
| Total debt | 2 | 1 | 1 | 1 |
| Total liabilities | 3 | 2 | 3 | 2 |
| 39 | 46 | 42 | 27 | |
| 0 | 0 | 0 | 1 | |
| -48.7% | -41.9% | -43.5% | -59.3% | |
| -63.7% | -50.9% | -51.8% | -71.8% |
Cash flow
| In millions of USD | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| -16 | -19 | -17 | -16 | |
| 0 | 0 | 0 | 0 | |
| -16 | -19 | -17 | -16 | |
| Dividends paid | – | – | – | – |
| – | – | – | – | |
| 9 | 5 | 4 | 3 |
Valuation
- –
- –
- –
- 0.3×
- –
- –
- 0.1×
- -343.8%
- -429.8%
- 0.0%
Profitability
- 0.0%
- 0.0%
- 0.0%
- 0.0%
- -82.2%
- -52.0%
- -66.4%
- -72.1%
- -83.5%
- –
Growth
- –
- –
- +7.7%
- –
- +201.9%
Financial health
- 0.1×
- 0.03
- 2.3%
- –
- 11.89
- 11.89
- 0.00
How it ranks in Healthcare
Each dot is where the company stands among every company over $300M in the sector. Further right is better.
Bottom 1%of 958
Bottom 21%of 889
Recent earnings
Our results feed has not updated since May 21, 2026. Results reported after that are not in this table yet.
| Date | EPS | Expected | Surprise |
|---|---|---|---|
| May 7, 2026 | -5.89 | -8.40 | +29.9% |
| Mar 26, 2026 | -10.53 | -9.80 | −7.4% |
| Oct 31, 2025 | -8.07 | -10.50 | +23.1% |
| Jul 31, 2025 | -0.33 | -0.28 | −17.9% |
| Apr 30, 2025 | -0.22 | -0.34 | +35.3% |
| Feb 27, 2025 | -0.30 | -0.35 | +14.3% |
| Oct 30, 2024 | -0.35 | -0.33 | −6.1% |
| Jul 31, 2024 | -0.31 | -0.36 | +13.9% |
News
No recent news on file.
Insider trades
Our insider feed has not updated since May 26, 2026. Trades filed after that are not listed yet.
No insider trades on file.
The seven classic investing rulebooks
2/7Passes 2 of 7. Each bar is how well the company fits that investor's published rules, from 0 to 100; 60 or more counts as a pass.
Warren Buffett
47No pass
Benjamin Graham
78Pass
Philip Fisher
39No pass
Peter Lynch
60Pass
Joel Greenblatt
50No pass
Charlie Munger
33No pass
Terry Smith
30No pass
Questions about enVVeno Medical
Is enVVeno Medical a good stock to buy?
A business with weak numbers that is not profitable yet. 2 of the 7 famous investors' published rulebooks we apply pass it. Whether it suits you depends on your goals and the price you pay; invest-like never tells anyone to buy or sell. The AI analysis lays out the case for and against. Read the enVVeno Medical AI analysis
What does enVVeno Medical do?
enVVeno Medical Corporation, a clinical-stage medical device company, focuses on the development of bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous disease. It is in Medical - Devices.
Does enVVeno Medical pay a dividend?
No. enVVeno Medical does not pay a dividend at the moment.
Is enVVeno Medical stock halal?
No. enVVeno Medical does not pass our halal screen: its cash and confirmed interest-bearing investments are 68% of its market value, at or above the 33% limit. How we check
How has enVVeno Medical stock done over the past year?
Down 73.5% over the past twelve months, to $6.52. It traded between $6.45 and $24.64 and is 73.5% below its high.
Who are enVVeno Medical's competitors?
The largest listed companies in the same industry are Boston Scientific, Koninklijke Philips, Steris and Zimmer Biomet Holdings. The peers table on this page compares their profit, growth and price with enVVeno Medical's.
Prices: daily closes to Nov 11, 2026. Fundamentals: company reports via invest-like data.